Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Cellexus Limited Announces New Directors to Enhance its’ Management Team

Published: Monday, December 09, 2013
Last Updated: Monday, December 09, 2013
Bookmark and Share
Appointment of Mr Stephen Lee as new Executive Technical Director and Dr Linda Cammish as a new Non-Executive Director.

Cellexus Limited has appointed Mr Stephen Lee as its’ new Executive Technical Director and Dr Linda Cammish as a new Non-Executive Director to enhance the Cellexus Management Team and Board of Directors as the Company expands.

Mr Lee is a Fellow of the Institute of Mechanical Engineers with over 40 years manufacturing management experience. His early career was at Pfizer R&D developing a range of new medical devices.

He was responsible for developing a number of pharmaceutical products at Bioprogress and managed the edible film manufacturing plant at BioTec Films LLC. He has been a Board member of a number of companies and is trustee of a pension fund.

Dr Cammish brings additional sales, marketing and business development experience to the Cellexus Board. With over 29 years experience in the life science area she has considerable expertise in growing businesses in this sector.

With extensive practical experience in senior leadership, business development, sales and marketing roles in companies including Millipore, PerSeptive Biosystems, Applied Biosystems and Abcam, she also has Board level experience and was more recently CEO at nanoTherics.

Mr Bob Cumming, Cellexus Limited General Manager, said in a statement, "Mr Lee has an excellent all round knowledge of engineering and its’ application to solving real problems in science and engineering and we are delighted that he is bringing this to Cellexus to further develop the Cellexus CellMaker range of single-use bioreactor products.”

He added, “Having achieved some significant milestones in product development and design to improve the flexibility of the CellMaker systems we are now in a phase of focussed commercialization of these new products so the addition of Dr Cammish to our Board of Directors, bringing a huge level of commercial experience in this sector to our Board team, is very timely. We are delighted to welcome both Mr Lee and Dr Cammish to their new roles to facilitate driving the Company forward through our next stage of growth.

Mr Lee added: "The Cellexus CellMaker products have been developed with next-generation technology and I am delighted to join the team to help further extend the product range and manage the production of the highly robust CellMaker systems to meet customers’ needs.”

Dr Cammish commented: “I am very pleased to be appointed as NED of the Cellexus Board. I look forward to working with the Directors and Management to drive growth through further sales of the Company’s proprietary single use disposable bioreactor products and the new products the Company will be launching.”

The Cellexus CellMaker range of automated systems apply a next-generation technology of single-use, disposable cell culture bioreactor bags which have highly efficient methods to mix and oxygenate. Whilst other systems require shakers, rockers, rollers or large environmental chambers, the CellMaker systems employ a novel airlift technology which is simple, scalable, inexpensive to use and proven to provide highly efficient cell culture to out-perform cell culture in flasks.

The CellMaker Bags, which are the unique single-use, disposable cell culture bags in which cells are grown in the CellMaker systems, enable fast set-up times, eliminate cleaning requirements and prevent cross-contamination.

The CellMaker systems very efficiently aerate the CellMaker Bags with controlled air flow providing oxygen for highly efficient cell growth with gentle and effective mixing to maintain cells in suspension.

Pressure control enhances oxygen availability to cells and decreases foaming whilst temperature control enables production of high yields of soluble protein under the most optimal conditions.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More Than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Cellexus Limited Appoints Dunn Labortechnik GmbH as Distributor in Germany
Cellexus Limited, a supplier of innovative single use, disposable bioreactors which are designed to simplify and improve cell culture and fermentation bioprocesses, has appointed Dunn Labortechnik GmbH as their distributor in Germany and Austria.
Wednesday, April 28, 2010
Scientific News
Head Injury Patients have Protein Clumps Associated with Alzheimer’s Disease
Scientists have revealed that protein clumps associated with Alzheimer's disease are also found in the brains of people who have had a head injury.
Exposure to Air Pollution 30 Years Ago Associated with Increased Risk of Death
Exposure to air pollution more than 30 years ago may still affect an individual's mortality risk today, according to new research from Imperial College London.
More Then 1 in 20 U.S. Children have Dizziness and Balance Problems
Researchers at NIH have found that girls have a higher prevalence of dizziness and balance problems compared to boys, 5.7 percent and 5.0 percent.
Biosensors on Demand
New strategy results in custom "designer proteins" for sensing a variety of molecules.
Low-Cost, Portable NQR Spectroscopy
A researcher at Case Western Reserve University is developing a low-cost, portable prototype designed to detect tainted medicines and food supplements that otherwise can make their way to consumers. The technology can authenticate good medicines and supplements.
Structure of Brain Plaques in Huntington's
Researchers at the University of Pittsburgh School of Medicine have shown that the core of the protein clumps found in the brains of people with Huntington's disease have a distinctive structure, a finding that could shed light on the molecular mechanisms underlying the neurodegenerative disorder.
Insights into the Function of the Main Class of Drug Targets
About thirty percent of all medical drugs such as beta-blockers or antidepressants interact with certain types of cell surface proteins called G protein coupled receptors.
Spero Therapeutics Announces $30 Million Series B Preferred Financing
Company has announced financing of $30 million to support development of novel therapies to treat gram-negative bacterial infections.
Unique Mechanism for a High-Risk Leukemia
Researchers uncovered the aberrant mechanism underlying a notoriously treatment-resistant acute lymphoblastic leukemia subtype; findings offer lessons for understanding all cancers.
Visualizing a Cancer Drug Target at Atomic Resolution
Using cryo-electron microscopy, researchers were able to view, in atomic detail, the binding of a potential small molecule drug to a key protein in cancer cells.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!